Pharmaceuticals

FDA approves Tris Pharma’s Onyda XR, a once-daily extended-release oral suspension for the treatment of ADHD

bexib
By bexib 0 Min Read

The approval of Onyda XR makes it the first non-stimulant liquid medication for attention-deficit hyperactivity disorder to be marketed in the United States.

You Might Also Like

Pharma Pulse 7/23/24: How safe are period tracking apps after Roe? Where to invest in this health trend, and more

UK researchers develop new tetanus test to identify global immunity gaps

Digital Drug News: Q&A with Rich Cooper

Advice for investors entering the weight loss market

New study finds AI-based colon cancer screening could help patients avoid chemotherapy

Share This Article
Previous Article Is the MEV monster under Bitcoin’s bed?
Next Article Vast lithium resources discovered in Pennsylvania could help ensure U.S. energy independence
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Indonesia’s OJK issues new regulations on alternative credit scoring
Fintech
Donald Trump signs executive orders on trade on his first day in office
Manufacturing
Fifth Third expands branch network and doubles technology capabilities
Banking
KeyBank increases technology spending by 10% in 2025
Banking